We explored the effectiveness of Evinacumab, a monoclonal antibody recently approved for treating severe high cholesterol. Our focus was on a 16-year-old girl from North India diagnosed with homozygous familial hypercholesterolemia (HoFH) at the tender age of two. Despite her long-standing battle with high cholesterol, traditional treatments, including medications and lifestyle changes, failed to bring her cholesterol levels down to the recommended guidelines.
Genetic testing confirmed that she had a significant mutation affecting her LDL receptor, contributing heavily to her condition. Her LDL cholesterol levels hovered around 320 mg/dL even after trying the maximum doses of established medications. As her health deteriorated, necessitating aortic valve replacement surgery, we introduced Evinacumab into her treatment regimen. What we observed was truly remarkable; her LDL cholesterol dropped by over 76%, reaching a level of 82 mg/dL that has remained stable over the last four months.
This case highlights Evinacumab as a promising option for managing patients with HoFH, especially for those who have not responded to existing therapies. This was also the first instance of a child in India receiving Evinacumab for this condition, potentially setting a precedent for future treatments.
Read More